Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis

Sunao Sugita, Chikako Taguchi, Hiroshi Takase, Kimitaka Sagawa, Jun Sueda, Kunihiro Fukushi, Naofumi Hikita, Toshiki Watanabe, Kyogo Itoh, Manabu Mochizuki

Abstract

Aims—To investigate the presence of soluble Fas ligand (sFasL) and soluble Fas (sFas) in ocular fluid of patients with uveitis.

Methods—Samples of aqueous humour (AH, n=17), vitreous fluid (n=9), and serum (n=60) were collected from patients with uveitis which included Behçet's disease, Vogt-Koyanagi-Harada disease, sarcoidosis, human T lymphotropic virus type 1 (HTLV-I) uveitis, sympathetic ophthalmia, HLA-B27 associated acute anterior uveitis, and ocular toxoplasmosis. The AH of patients with age related cataract without uveitis obtained during cataract surgery was used as controls (n=20). The amounts of sFasL and sFas were measured by enzyme linked immunosorbent assay.

Results—Significant amounts of sFasL were detected in AH of patients with age related cataract (non-uveitis group). sFasL was also detected in AH of patients with uveitis, though the amounts were slightly lower than those in the non-uveitis group. On the other hand, the levels of sFas in AH of patients with uveitis were significantly higher than those in controls. As for the disease activity, the levels of sFasL and sFas in the vitreous fluid of patients with active uveitis were significantly higher than those in inactive uveitis. sFasL in the serum of healthy donors and patients with uveitis was below detectable levels, except for patients with HTLV-I uveitis who had significant amounts of sFasL in the serum. The levels of sFas in the serum of patients with Behçet's disease, sarcoidosis, and HTLV-I uveitis were significantly higher than those of healthy donors.

Conclusions—sFasL is present in the AH of non-uveitic eyes with age related cataract. Intraocular levels of sFasL and sFas are significantly increased in uveitis, particularly in active uveitis. These data suggest that intraocular sFasL and sFas may have a regulatory role in uveitis.

(Br J Ophthalmol 2000;84:1130-1134)

testinal peptide,⁴ and TGF- β ⁵ (transforming growth factor β). More recently, natural killer (NK) cell inhibitory protein was found in the aqueous humour.⁶

Fas (APO-1, CD95) is a type I integral membrane protein,⁷⁻⁹ and a member of the tumour necrosis factor (TNF) receptor family. FasL (FasL/APO-1, CD95L) is a type II integral membrane protein and a member of the TNF family, which includes TNF- α , TNF- β , and the ligands for CD27 (CD70)¹⁰ and CD40 (CD154).¹¹ Interaction between Fas positive cells and FasL positive cells caused intracellular signal transduction in the former cells, which induces apoptosis of the Fas positive cells.^{12,13} Fas is expressed on various immunocytes including lymphocytes when they are activated, and FasL is expressed on activated T cells and NK cells.^{14,15} In addition, Fas is expressed on resident cells in various tissues including the liver, thymus, heart, ovary, and kidney,¹⁶ whereas expression of FasL has been demonstrated on cells in the testis¹⁷ and eyes, such as cornea, iris ciliary body, and retina.¹⁸ In fact, it was shown that when inflammatory cells entered the anterior chamber of the eye in response to viral infection, they underwent apoptosis that was dependent on Fas-FasL and intraocular tissues were protected from tissue damages.¹⁸

Activated lymphocytes have been shown to release soluble forms of FasL (sFasL), which is capable of inducing apoptosis of Fas positive cells.^{19,20} sFasL is also known to induce activation of nuclear factor κ B (NF- κ B) and/or IL-8 secretion.²¹ Thus, sFasL has biological activities, though the presence and possible function of sFasL in the eye have not been clarified yet. The present study was, therefore, aimed at obtaining insights into the presence of soluble forms of FasL and Fas in the eye by measuring their levels in ocular fluid of patients with uveitis.

Materials and methods

AH samples (100–200 μ l) were collected from patients with age related cataract (n=20) during cataract surgery, and from patients with various types of uveitis (n=17). The cataract patients had no clinical history of uveitis or systemic diseases, and the group was designated as a non-uveitis group in this study. The patients with uveitis had active intraocular inflammation, but were not treated with topical and systemic therapy at the time of aqueous humour sampling. The patients with uveitis included Behçet's disease (n=2), Vogt-Koyanagi-Harada disease (VKH; n=3), sarcoidosis (n=4), human T lymphotropic virus

Department of Visual Science, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan
S Sugita
H Takase
M Mochizuki

Department of Ophthalmology, Kurume University School of Medicine, Fukuoka, Japan
C Taguchi
J Sueda
K Fukushi
N Hikita

Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
K Itoh

Department of Transfusion Medicine, Kurume University School of Medicine, Fukuoka, Japan
K Sagawa

Department of Pathology, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan
T Watanabe

Correspondence to:
Sunao Sugita, Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-0034, Japan
sunaoph@med.tmd.ac.jp

Accepted for publication
13 April 2000

The eye is a classic example of an immunologically privileged site.¹ The aqueous humour participates in the local defence system of the eye and protects intraocular tissues from inflammation and immune mediated damage. The aqueous humour contains immunosuppressive factors, such as α melanocyte stimulating hormone,² glucocorticoids,³ vasoactive in-

type 1 (HTLV-I) uveitis (n=3), sympathetic ophthalmia (SO; n=3), and HLA-B27 associated acute anterior uveitis (AAU; n=2).

When vitreous surgery was performed in the patients with uveitis, vitreous fluid samples (200–1000 µl) were collected from the patients during the surgery (n=9). All the patients had no systemic corticosteroids at the time of surgery. The patients included those with Behçet's disease (n=2), sarcoidosis (n=3), HTLV-I uveitis (n=2), and SO (n=2). At the time of the vitreous surgery, uveitis activity was active in four patients (two patients with Behçet's disease, one patient with sarcoidosis, and one patient with HTLV-I uveitis) and inactive in five patients. In the two patients with Behçet's disease, vitrectomy was performed despite the fact that patients had active uveitis because they developed retinal detachment associated with a macular hole. In the other two patients with active uveitis, vitrectomy was carried out aiming at cytological examination because malignancy was suspected clinically but not detected. The activity of the uveitis referred to the classification of posterior uveitis by Nussenblatt *et al.*²² and all patients with active uveitis had vitreous haze of grade 2 or 3.

We also tested the serum samples from the following different sets of patients: Behçet's disease (n=10), VKH (n=10), sarcoidosis (n=10), HTLV-I uveitis (n=10), AAU (n=10), ocular toxoplasmosis (n=10), and healthy donors (n=10). The patients except for healthy donors had active uveitis and had no systemic therapy when their serum samples were collected.

The average age of the cataract patients was 76.5 years, and that of all uveitis patients was 44.0 years.

Informed consent was given by each patient before sampling. The research followed the tenets of the Declaration of Helsinki. This study was approved by the institutional ethics committee of Kurume University School of Medicine.

After the aqueous humour and the serum samples were centrifuged at 3000 rpm for 5 minutes and the vitreous fluid was centrifuged at 10 000 rpm for 5 minutes, the supernatant was collected and stored at –80°C until use. The samples used in this study were collected between 1995 and 1997, and assayed in 1998. The samples were thawed only once, and used for assay.

ELISA FOR sFASL AND sFAS

The amounts of sFasL were determined by a sandwich enzyme linked immunosorbent assay (ELISA) using two anti-human FasL monoclonal antibodies, NOK-1 (mouse IgG1, κ) and NOK-3 (mouse IgM, κ).^{19–20} The antibodies were provided by Dr Hideo Yagita, Department of Immunology, Juntendo University School of Medicine. The measurement of sFasL was carried out by a sandwich ELISA as follows. A 96 well plate was coated with NOK-3 anti-human FasL antibody (10 µg/ml diluted with phosphate buffer saline, PBS) overnight at 4°C. After washing the plate with

PBS containing 0.05% Tween 20 (T-PBS), the wells were blocked by skimmed milk solution (Block Ace; Snow Brand Milk Co, Sapporo, Japan) for 2 hours at 37°C. Ocular fluid and serum samples were diluted twice with 1% bovine serum albumin (BSA)/PBS. Fifty µl of the samples and standard sFasL (diluted with 1% BSA/PBS) were added to the well and incubated for 1 hour at room temperature. After washing with T-PBS, biotinylated NOK-1 anti-human FasL antibody (5 µg/ml containing 5% mouse serum) was added and incubated for 1 hour at room temperature. The wells were washed five times with T-PBS and incubated with 50 µl avidin-peroxidase (Sigma Chemical Co, St Louis, MO, USA) for 1 hour at room temperature. Peroxidase activity was detected using a peroxidase detecting kit (Sumitomo Co, Tokyo, Japan). The absorbance was measured at 450 nm using an automated ELISA reader.

The specificity of the sandwich ELISA methods used in the study was evaluated as follows. The human FasL cDNA transfectant cells (hFasL/L5178Y) were cultured in RPMI-1640 medium containing 10% FCS, 100 U/ml penicillin G, and 50 mg/ml streptomycin. The supernatant of the culture was collected and used as positive controls. Commercial recombinant human TNF-α (Endogen, MA, USA) and the culture supernatants of human CD70 (CD27 ligand)/BCMGSneo in 300–19 cells and human CD154 (CD40 ligand)/BCMGSlyg in 300–19 cells which contained CD70 and CD154, respectively, were used as negative controls. The CD70/BCMGSneo in 300–19 cells and human CD154/BCMGSlyg in 300–19 cells were provided by Dr Tetsuji Kobata, Department of Immunology, Juntendo University School of Medicine. The present sandwich ELISA methods were able to detect sFasL from the culture medium of the hFasL/L5178Y cells, but not other members of TNF family—CD70 and CD154 (data not shown).

The amounts of sFas in the supernatant of samples measured by ELISA using a commercial assay kit (MBL, Nagoya, Japan).

STATISTICAL ANALYSIS

Statistical analysis was performed by the Mann–Whitney test. The difference between the two groups (controls versus uveitis) compared was determined to be statistically significant, when the p value was less than 0.05.

Results

The levels of sFasL and sFas in ocular fluid of the non-uveitis group and the patients with uveitis were quantified by ELISA. Among the non-uveitis group of 20 patients with age related cataract without ocular inflammation, 11 patients had detectable levels of sFasL in aqueous humour ranging from 223 to 1343 pg/ml and the other nine patients had undetectable levels of sFasL (Fig 1A). The mean level of sFasL in aqueous humour was 273 (SD 341) pg/ml. This indicates that more than one half of the non-uveitis group had significant amounts of sFasL in aqueous humour. As for

Figure 1 (A) Soluble Fas ligand (sFasL) in the aqueous humour. Non-uveitis indicates samples from patients with age related cataract ($n=20$). Uveitis indicates samples obtained from patients with the following ($n=17$): Behçet's disease, Vogt-Koyanagi-Harada disease, sarcoidosis, sympathetic ophthalmia, HLA-B27 associated acute anterior uveitis, and HTLV-I uveitis. Bar indicates average values. (B) Soluble Fas (sFas) in the aqueous humour. Non-uveitis and uveitis indicate samples from patients with age related cataract ($n=20$) and those with uveitis ($n=17$), respectively, as in (A). Bar indicates average values and an asterisk indicates statistical significance ($p < 0.0005$).

the patients with uveitis, significant amounts of sFasL were detected in six of 17 patients and the mean level of sFasL in aqueous humour was 132 (202) pg/ml. There was no statistically significant difference in the sFasL levels in aqueous humour between the two groups (Fig 1A).

sFas in aqueous humour in the majority of non-uveitis patients was below detectable levels (Fig 1B). In contrast, all patients with uveitis had high levels of sFas in the aqueous humour (Fig 1B). The mean values of sFas in aqueous humour of non-uveitis patients and uveitis patients were 67 (129) and 1132 (881), respectively. The difference between the two groups was statistically significant ($p < 0.0005$).

The levels of sFasL and sFas in the vitreous fluid were examined in relation to the activity of uveitis. When the eye had no signs and

Figure 2 (A) Soluble Fas ligand (sFasL) in the vitreous fluid. Active uveitis ($n=4$) and inactive uveitis ($n=5$) indicate samples obtained from patients with the following: Behçet's disease, HTLV-I uveitis, sarcoidosis, and sympathetic ophthalmia. Bar indicate average values and an asterisk indicates statistical significance ($p < 0.05$). (B) Soluble Fas (sFas) in the vitreous fluid. Active uveitis ($n=4$) and inactive uveitis ($n=5$) indicate samples obtained from patients as in (A).

symptoms of uveitis for the past 3 months, the eye was considered to be inactive. On the other hand, if the eye had inflammation in the anterior segment, vitreous or the posterior segment at the time of vitreous surgery, it was classified as having active uveitis. Significant amounts of sFasL were detected in the vitreous in all four patients with active uveitis, while only one of five patients with inactive uveitis had detectable levels of sFasL (Fig 2A). The difference between the two groups was statistically significant ($p < 0.05$). Similar to sFasL, the levels of sFas in the vitreous were significantly higher in patients with active uveitis than in those with inactive uveitis ($p < 0.05$) (Fig 2B).

The serum levels of sFasL and sFas were examined in healthy donors and patients with various types of uveitis (Fig 3A and B). The serum levels of sFasL in healthy donors were undetectable or very low. Similarly, all uveitis entities except for HTLV-I uveitis exhibited undetectable or low levels of sFasL in the

Figure 3 (A) Soluble Fas ligand (sFasL) in the serum. Healthy donors ($n=10$), Behçet = Behçet's disease ($n=10$), VKH = Vogt-Koyanagi-Harada disease ($n=10$), Sar = sarcoidosis ($n=10$), AAU = HLA-B27 associated acute anterior uveitis ($n=10$), HTLV-I = HTLV-I uveitis ($n=10$), Toxo = ocular toxoplasmosis ($n=10$). Bar indicates average values and an asterisk indicates statistical significance as compared with control ($p<0.05$). (B) Soluble Fas (sFas) in the serum. Healthy donors ($n=10$), Behçet = Behçet's disease ($n=10$), VKH = Vogt-Koyanagi-Harada disease ($n=10$), Sar = sarcoidosis ($n=10$), AAU = HLA-B27 associated acute anterior uveitis ($n=10$), HTLV-I = HTLV-I uveitis ($n=10$), Toxo = ocular toxoplasmosis ($n=10$). Bar indicates average values and an asterisk indicates statistical significance as compared with control ($p<0.05$).

serum. The levels of sFasL in the serum of patients with HTLV-I uveitis were significantly higher than those of healthy donors ($p<0.05$). In contrast, significant amounts of sFas were determined in the serum of healthy donors and patients with uveitis. The levels of sFas in the serum of patients with Behçet's disease, sarcoidosis, and HTLV-I uveitis were significantly higher than those of healthy donors ($p<0.05$).

Discussion

The present study demonstrated for the first time significant amounts of sFasL in aqueous humour of patients with age related cataract who had no history of ocular inflammation. This indicates that aqueous humour of the human eye in normal condition contains significant amounts of sFasL. It has been well established that the interaction between FasL and Fas positive cells causes apoptotic cell death of Fas positive cells.^{23 24} Although the capacity of naturally processed sFasL to induce

apoptotic cell death is considered to be much lower than that of membrane bound FasL, sFasL was shown to have biological activities similar to membrane bound FasL.^{19 20 25} Thus, sFasL in aqueous humour might be one of the factors which plays a part in inducing apoptotic cell death of Fas positive infiltrating cells in the eye, thereby regulating ocular inflammation. As for the source of sFasL in aqueous humour in the non-uveitis group, we consider that it is locally produced in the eye because sFasL was not detected in the serum. In normal conditions, the corneal endothelium and resident cells in the iris-ciliary body have been reported to express FasL constitutively.¹⁸ The extracellular domain of FasL is considered to be processed by a specific matrix metalloproteinase (MMP)-like enzyme and released as a soluble form—that is, sFasL. In fact, the MMPs were found in normal human aqueous humour and patients with uveal inflammation.²⁶ Therefore, it is likely that sFasL detected in aqueous humour in non-uveitic patients is released from the resident cells surrounding aqueous humour, such as the corneal endothelium and iris-ciliary body. In contrast with sFasL, sFas in aqueous humour in non-uveitic patients was undetectable or at minimal levels. These results are consistent with the fact that immunocytes are absent in aqueous humour of normal eyes.

The present study showed that in aqueous humour of patients with uveitis sFasL was relatively low but sFas was very high. As mentioned above, sFasL is considered to interact with Fas positive inflammatory cells in aqueous humour. The interaction between sFasL and Fas positive inflammatory cells in aqueous humour of uveitis patients may cause apoptotic cell death of the inflammatory cells and participate in the downregulation of ocular inflammation. The relatively low amounts of sFasL in aqueous humour of patients with uveitis can be a result of consumption of sFasL in these processes. On the other hand, sFas was reported to protect Fas mediated apoptosis.^{27 28} Therefore, the high amounts of sFas found in the aqueous humour of patients with uveitis may counteract the apoptosis mediated downregulation of intraocular inflammation.

As for the serum levels of sFasL, they were very low in healthy donors as well as in patients with uveitis except for those with HTLV-I uveitis. Although a few studies have determined the serum levels of sFasL, available data indicate that significant levels of sFasL in the serum were detected in the patients with specific types of leukaemia.²⁹ HTLV-I uveitis is not leukaemia, but significant amounts of HTLV-I infected lymphocytes were detected in the peripheral blood of patients with HTLV-I uveitis.³⁰ HTLV-I infected lymphocytes are activated lymphocytes with FasL expression, and this may explain the high amounts of sFasL in the serum of patients with HTLV-I uveitis. In contrast with sFasL, significant amounts of sFas were found in the serum of healthy donors and patients with uveitis. Nakamura³¹ reported that the serum levels of sFas in patients with Behçet's disease were sig-

nificantly higher than those of controls. This is in accord with the present results. The present study further determined the serum levels of sFas in many other entities of uveitis, and sarcoidosis and HTLV-I uveitis exhibited significantly larger amounts of sFas in the serum than in healthy donors. Serum levels of sFas in VKH were also much higher than those of healthy donors, although not statistically significant. Recent studies have shown high levels of sFas in the serum in some autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis,³² probably reflecting continuous activation of immunocytes in these patients. The present results of high levels of the serum sFas in Behçet's disease, sarcoidosis, and HTLV-I uveitis were in accord with these previous results, suggesting a systemic nature of these entities of uveitis with persistent activation of the immune system. In contrast with these systemic diseases, low levels of sFas in the serum were found in uveitis localised in the eye, such as ocular toxoplasmosis and AAU.

In conclusion, sFasL is present in the aqueous humour of the eyes of non-uveitic patients. Intraocular levels of sFasL and sFas are significantly increased in uveitis, particularly in active uveitis. These data suggest that intraocular sFasL and sFas may have a regulatory role in uveitis.

We thank Drs Hideo Yagita, Tetsuji Kobata, of the Department of Immunology, Juntendo University School of Medicine for anti-human FasL monoclonal antibodies (NOK-1, 2, 3), culture supernatants of human CD70 (CD27 ligand)/BCMGSneo in 300–19 cells, and human CD154 (CD40 ligand)/BCMGSlyg in 300–19 cells.

- Barker CF, Billingham E. Immunologically privileged sites. *Adv Immunol* 1977;25:1–4.
- Taylor AW, Streilein JW, Cousins SW. Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. *Curr Eye Res* 1992;11:199–205.
- Kniesly TL, Hosoi J, Nazareno R, et al. The presence of biologically significant concentrations of glucocorticoids but little or no cortisol binding globulin within aqueous humor: relevance to immune privilege in the anterior chamber of the eye. *Invest Ophthalmol Vis Sci* 1994;35:3711–6.
- Taylor AW, Streilein JW, Cousins SW. Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of aqueous humor. *J Immunol* 1994;153:1080–5.
- Cousins SW, McCabe MM, Danielpour D, et al. Identification of transforming growth factor beta as an immunosuppressive factor in aqueous humor. *Invest Ophthalmol Vis Sci* 1991;32:2201–11.
- Rajendra SA, Niederkorn JY. Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. *J Immunol* 1996;156:2667–73.
- Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen codownregulated with the receptor of tumor necrosis factor. *J Exp Med* 1989;169:1747–56.
- Nagata S, Golstein P. The Fas death factor. *Science* 1995;267:1449–56.
- Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. *Cell* 1994;76:959–62.
- Lens SM, de Jong R, Hooibrink B, et al. Phenotype and function of human B cells expressing CD70 (CD27 ligand). *Eur J Immunol* 1996;26:2964–71.
- Clark LB, Foy TM, Noelle RJ. CD40 and its ligand. *Adv Immunol* 1996;63:43–78.
- Hanabuchi S, Koyanagi M, Kawasaki A, et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. *Proc Natl Acad Sci USA* 1994;91:4930–4.
- Arase H, Arase N, Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. *J Exp Med* 1995;181:1235–8.
- Suda T, Okazaki T, Naito Y, et al. Expression of the Fas ligand in cells of T cell lineage. *J Immunol* 1995;154:3806–13.
- Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. *Cell* 1993;75:1169–78.
- Watanabe-Fukunaga R, Brannan CI, Itoh N, et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. *J Immunol* 1992;148:1274–9.
- Belgrau D, Gold D, Selawry H, et al. A role for CD95 ligand in preventing graft rejection. *Nature* 1995;377:630–2.
- Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. *Science* 1995;270:1189–92.
- Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. *J Exp Med* 1995;182:1777–83.
- Tanaka M, Suda T, Takahashi T, et al. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. *EMBO (Eur Mol Biol Organ) J* 1995;14:1129–35.
- Abreu-Martin MT, Vidrich A, Lynch DH, et al. Divergent induce of apoptosis and IL-8 secretion in HT-29 cells in response to TNF- α and ligation of Fas antigen. *J Immunol* 1995;155:4147–54.
- Nussenblatt RB, Palestine AG, Chan CC, et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. *Ophthalmology* 1985;92:467–71.
- Nagata S, Golstein P. The Fas death factor. *Science* 1995;267:1449–56.
- Craig BT. Apoptosis in the pathogenesis and treatment of disease. *Science* 1995;267:1456–62.
- Tanaka M, Itai T, Adachi M, et al. Downregulation of Fas ligand by shedding. *Nat Med* 1998;4:31–6.
- Di Girolamo N, Verma MJ, McCluskey PJ, et al. Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. *Curr Eye Res* 1996;15:1060–68.
- Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. *Science* 1994;263:1759–62.
- Cascino I, Fiucci G, Papoff G, et al. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. *J Immunol* 1995;154:2706–13.
- Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. *Nat Med* 1996;2:317–22.
- Ono A, Mochizuki M, Yamaguchi K, et al. Immunologic and virologic characterization of the primary infiltrating cells in the aqueous humor of human T cell leukemia virus type-1 uveitis. *Invest Ophthalmol Vis Sci* 1997;38:676–89.
- Nakamura S. Cell biology in endogenous uveitis. *J Jpn Ophthalmol Soc* 1997;101:975–86.
- Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. *Science* 1994;263:1759–62.